Collegium Pharma Revenue, Profits - COLL Quarterly Income Statement

Add to My Stocks
$14.2 $0.04 (0.28%) COLL stock closing price Sep 18, 2018 (Closing)

Financial analysis of Collegium Pharma involves more than just checking the Collegium Pharma stock price, by looking at the financial statements of the company in detail. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the COLL stock is bound to reflect the impact of the QOQ growth of 14.6%. One also needs to look at Collegium Pharma assets, operating expenses and Collegium Pharma free cash flow. The Collegium Pharma profit and loss statement shows revenue of $73.06M for 2018 Q2. Revenue has grown by 14.6% QoQ for COLL stock.

View and download details of revenue and profits for Collegium Pharma for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Collegium Pharma Revenues or Net Sales
73.06M63.75M10.79M11.95M3.56M2.17M1.3M---
Cost Of Goods Sold (COGS)46.84M43.1M1.1M-------
Collegium Pharma Gross Profit
26.22M20.64M9.71M11.39M2.98M1.8M1.12M---
Research & Development Expense2.24M2.26M2.21M2.06M2.17M2.13M3.33M3.25M4.3M4.06M
Selling General & Admin Expense31.28M31.58M25.1M22.75M22.06M22.84M25.38M23.56M20.17M11.52M
Income Before Depreciation Depletion Amortization-7.29M-13.2M-17.59M-13.43M-21.25M-23.17M-27.59M-26.44M-24.47M-15.58M
Depreciation Depletion Amortization----------
Non Operating Income----------
Interest Expense6.16M5.7M-0.2M-0.16M-0.13M-0.09M-0.01M---
Collegium Pharma Pretax Income
-13.06M-18.65M-17.41M-13.26M-21.12M-23.07M-27.56M-26.44M-24.52M-15.65M
Provision for Income Taxes----------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-13.06M-18.65M-17.4M-13.26M-21.12M-23.08M-27.56M-26.44M-24.52M-15.65M
Extraordinary Items & Discontinued Operations----------
Collegium Pharma Profit/ Loss (Net Income)
-13.06M-18.65M-17.4M-13.26M-21.12M-23.08M-27.56M-26.44M-24.52M-15.65M
Average Shares used to compute Diluted EPS32.97M32.9M32.49M29.75M29.44M29.35M27.1M23.46M23.42M23.13M
Average Shares used to compute Basic EPS32.97M32.9M32.49M29.75M29.44M29.35M27.1M23.46M23.42M23.13M
Income Before Nonrecurring Items-8.46M-18.65M-17.4M-13.26M-21.12M-23.08M-27.56M-26.44M-24.52M-15.65M
Income from Nonrecurring Items-4.6M---------
Collegium Pharma Earnings Per Share Basic Net
-0.40-0.57-0.54-0.45-0.72-0.79-1.02-1.13-1.05-0.68
Collegium Pharma Earnings Per Share Diluted Net
-0.40-0.57-0.54-0.45-0.72-0.79-1.02-1.13-1.05-0.68
EPS Diluted Before Nonrecurring Items-0.26-0.57-0.54-0.45-0.72-0.79-1.02-1.13-1.05-0.68
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Collegium Pharma stock analysis involves checking at least a few of the important things like:

  • Topline: A growing topline, as seen from the Collegium Pharma revenue chart, as is the case with Collegium Pharma indicates a growing business. One needs to compare the QoQ topline or sales growth of COLL stock with its peers like CYNA stock and RIGL stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. COLL stock had a healthy bottom line growth.

The income statement is also called statement of revenue and expense. The COLL financials along with Collegium Pharma historical stock prices provide a lot of details about the firm.

Collegium Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
2.93
Dividend Yield
0%